Lactobacillus GG in inducing and maintaining remission of Crohn's disease.
Lactobacillus GG in inducing and maintaining remission of Crohn's disease.
复制标题
DOI：
10.1186/1471-230x-4-5
复制
发表时间：
2004-03-15
影响因子：
2.4
通讯作者：
Rath HC
中科院分区：
文献类型：
--
作者：
Schultz M;Timmer A;Herfarth HH;Sartor RB;Vanderhoof JA;Rath HC
实验研究表明，管腔抗原参与慢性肠道炎性疾病，如克罗恩病和溃疡性结肠炎。通过抗生素或益生菌治疗改变肠道微生物菌群可诱导和维持缓解。这项随机、安慰剂对照试验的目的是确定口服乳酸杆菌GG（L。GG）以诱导或维持医学诱导的缓解。11名中度至活动性克罗恩病患者参加了这项试验，接受L。GG（2 × 109 CFU/天）或安慰剂治疗6个月。所有患者都开始逐渐减少类固醇方案，并在开始益生菌/安慰剂药物治疗前一周接受抗生素治疗。主要终点是持续缓解，定义为6个月随访访视时无复发。复发定义为CDAI增加>100分。5/11例患者完成研究，每组中有2例患者持续缓解。L组中位复发时间为16 ± 4周。GG组为12 ± 4.3周，安慰剂组为12 ± 4.3周（p = 0.5）。在这项研究中，我们不能证明L的益处。GG诱导或维持CD的药物诱导缓解。
Experimental studies have shown that luminal antigens are involved in chronic intestinal inflammatory disorders such as Crohn's disease and ulcerative colitis. Alteration of the intestinal microflora by antibiotic or probiotic therapy may induce and maintain remission. The aim of this randomized, placebo-controlled trial was to determine the effect of oral Lactobacillus GG (L. GG) to induce or maintain medically induced remission. Eleven patients with moderate to active Crohn's disease were enrolled in this trial to receive either L. GG (2 × 109 CFU/day) or placebo for six months. All patients were started on a tapering steroid regime and received antibiotics for the week before the probiotic/placebo medication was initiated. The primary end point was sustained remission, defined as freedom from relapse at the 6 months follow-up visit. Relapse was defined as an increase in CDAI of >100 points. 5/11 patients finished the study, with 2 patients in each group in sustained remission. The median time to relapse was 16 ± 4 weeks in the L. GG group and 12 ± 4.3 weeks in the placebo group (p = 0.5). In this study we could not demonstrate a benefit of L. GG in inducing or maintaining medically induced remission in CD.